Hatswell, A.J., Thompson, G.J., Maroudas, P.A., Sofrygin, O. and Delea, T.E. (2017) Estimating Outcomes and Cost Effectiveness Using a Single-Arm Clinical Trial: Ofatumumab for Double-Refractory Chronic Lymphocytic Leukemia. Cost Effectiveness and Resource Allocation, 15, 8.
https://doi.org/10.1186/s12962-017-0071-x

has been cited by the following article:

• TITLE: Parametrization of Survival Measures (Part II): Single Arm Studies

  AUTHORS: Andras Szasz, Gyula P. Szigeti, Marcell A. Szasz

  KEYWORDS: Single-Arm Clinical Trial, Survival-Time, Decomposition of Survival Curves, Personalized Treatment, Observational Trial

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.11 No.5, May 27, 2020

  ABSTRACT: In some clinical applications in oncology randomized, double armed, and double-blind trials are not possible. In case of device applications, double-blinded conditions are nonrealistic, and with many times the randomization also has complications due to the high-line treatments where the reference cohort is not available; the active “arm” has mainly palliative initiative. Sometimes highly personalized therapies block the collection of the homogeneous group and limit its double-arm randomization. Our objective is to discuss the situations of the single arm evaluation and to give methods for the mining of information from this to increase the level of evidence of the measured dataset. The basic idea of the data-separation is the appropriate parameterization of the non-parametric Kaplan-Meier survival pattern by the poly-Weibull fit.